This session explores the advantage of transitioning Research Science Liaisons (RSLs) from early clinical development engagement to optimize scientific engagement pre-launch and beyond. Attendees will gain insights into how early RSL engagement with KOLs and PIs can evolve into a true Medical Science Liaison (MSL) role to drive clinical trial success, support market access, and foster future advocacy. The presentation will outline best practices for transitioning from RSLs to MSLs, highlighting their impact on accelerating clinical trials and enhancing commercialization strategies.
